On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...

GSK has announced positive results from a phase III trial of its depemokimab treatment for chronic rhinosinusitis with nasal ...

GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps: London, UK Tuesday, October 15, 2024, 10:00 Hrs [IST] GSK ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

GSK said its depemokimab respiratory drug met the main objectives in two late-stage clinical trials, showing efficacy for the treatment of chronic rhinosinusitis with nasal polyps.

GSK said that both the Anchor-1 and Anchor-2 trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score after 52 weeks, as well as a change in mean nasal ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic ...